For primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. Sold as Rivfloza. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Nedosiran Sodium (sold as Rivfloza), first approved Sep 29, 2023, with 1 new use approved and 0 published complete response letters.
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
